Oscar Health Re-Rates to $30, But Risk-Adjustment and MLR Headwinds Loom

What happened

Oscar Health's stock has rerated to the $30 range following strong Q1'26 results that included a 70.5% MLR and $679M net income. However, the Q1 performance was inflated by $68M of favorable reserve development and a seasonally low loss ratio, masking structural pressure from rising risk-adjustment payables and plan mix shifts. Risk Adjustment Transfer dynamics are expected to pressure EPS and margins in Q2 and beyond, with the net risk-adjustment payable already at $3.97B after a $1.44B build in Q1. Management's FY2026 MLR guidance of 82.4%-83.4% implies a sharp normalization from Q1's 70.5%, and the company has disclosed that enhanced APTC expiration has already reduced membership post-open enrollment. The stock's re-rating reduces the asymmetry that existed at lower prices, leaving limited upside absent flawless execution on risk-score capture and cost control.

Implication

The re-rating to $30 reflects investor optimism that Q1 profitability is sustainable, but the base case from filings points to material MLR normalization and continuing risk-adjustment drag. With the net risk-adjustment payable compounding and membership declining after APTC expiration, the risk/reward is now skewed to the downside. Investors should consider reducing positions or setting strict stop-losses ahead of Q2 earnings, as a miss on MLR or risk-adjustment could trigger a sharp de-rating back toward $20.

Thesis delta

The master report's POTENTIAL SELL thesis is now playing out: the stock has rerated to the upper end of the bull case ($30), but the fundamental headwinds remain intact. The risk-adjusted asymmetry has narrowed, making the near-term path more dependent on continuous execution rather than a valuation re-rating. If Q2 results show MLR above 80% and further risk-adjustment build, the equity could quickly lose its recent gains.